The Jacobs School of Medicine
and Biomedical Sciences is a key player and significant
contributor to UB 2020, the university’s strategic
Under this plan, the medical school and the university’s four other health sciences schools will relocate to the Buffalo Niagara Medical Campus, close to key hospital and research affiliates.
As part of Phase 1 of the plan, the university partnered with
the Kaleida Health System to build the Gates Vascular Institute and
Clinical and Translational Research Center, which opened in
September 2012. This is the centerpiece of a campus where
world-class medical treatments, education and research are taking
Under Phase 2, the medical school will move to the Downtown Campus in early 2017, followed by the School of Nursing and UB’s three other health sciences schools (dentistry, public health and health professions, and pharmacy and pharmaceutical sciences).
Each of the schools will be within walking distance of UB’s New York State Center of Excellence in Bioinformatics and Life Sciences, Roswell Park Cancer Institute, Hauptman Woodward Medical Research Institute and our hospital partners, as well as other UB biomedical facilities.
This is an exciting time in our school’s history as we plan for a future that builds upon its proud legacy of teaching, patient care and scientific discovery.
The plan has identified eight cross-disciplinary areas of strength indigenous to UB.
Each strength serves as an infrastructure for pulling together researchers from across the university to work cooperatively in pursuit of solutions to wide-ranging problems through a nontraditional collaborative approach.
Our school is involved in five of the strengths:
Efforts to develop these strengths involve strategic faculty
recruitment and the planning of facilities to support their
research and teaching activities. This includes partnering with
Kaleida Health to build a $291 million combined facility on our
Downtown Campus, which opened in September 2012.
The new institute and
center brings together physicians and researchers in a
collaborative effort to deliver state-of-the-art clinical care,
produce major breakthroughs on the causes and treatment of vascular
disease and spin-off new biotechnology businesses.